Davis George Eric 4

What Happened
George Davis, EVP and Chief Legal Officer of BioMarin Pharmaceutical (BMRN), reported two types of transactions: he was credited with 15,224 performance-based restricted stock units (RSUs) on Feb 25, 2026 (three awards of 6,177; 6,675; and 2,372 RSUs) and sold 26,061 shares in an open-market transaction on Feb 26, 2026 at $61.36 per share for total proceeds of approximately $1,599,103. The RSUs were reported at $0.00 acquisition price because they are awards, not cash purchases.

Key Details

• Transactions reported: RSU awards (A) totaling 15,224 RSUs on 2026-02-25; open-market sale (S) of 26,061 shares on 2026-02-26 at $61.36/share (≈ $1,599,103).
• RSUs were "earned" per company certification on Feb 25, 2026 but shown as $0.00 because they are awards, not purchases.
• Vesting: the earned RSUs vest on March 15, 2026 subject to continued service (see footnote F3); they are convertible 1:1 into common shares when vested (F1).
• Performance basis: the RSUs were earned under performance metrics covering 2023–2025 (relative total shareholder return, development goals, and core operating margin — footnotes F2–F5).
• Shares owned after the sale: not specified in the provided Form 4 excerpt.
• Filing: Report filed Feb 26, 2026 (covers transactions dated Feb 25–26, 2026); no late-filing indication in the excerpt.

Context
The RSU entries are awards earned under multi-year performance criteria but are not yet vested as of the report date; they become actual shares only upon vesting. The Feb 26 transaction was an open-market sale (a routine disposition of existing shares) and should not be taken as commentary on future company performance. Purchases typically carry more immediate bullish signal than awards or sales; this filing mainly documents a sale plus recognition of earned, unvested performance RSUs.